Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations

Clinical trial NCT05904730 · COMPLETED

Trial details

NCT number: NCT05904730
Sponsor: Lynkcell Europe
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Breast Cancer Ovarian Cancer Breast Neoplasms Ovarian Neoplasms BRCA Mutation HER2-positive Breast Cancer HER2-negative Breast Cancer HER-2 Protein Overexpression

Start date: 2023-07-11
Primary completion: 2024-11-09
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.